. Efficacy of quinolone prophylaxis in neutropenic cancer patients: a meta-analysis . J Clin Oncol 1998 ; 16 : 1179 – 1187 . 32. Imrie KR Prince HM Couture F . Effect of antimicrobial prophylaxis on hematopoietic recovery following autologous
Search Results
Antibacterial Prophylaxis in Patients with Neutropenia
Brahm H. Segal and Alison G. Freifeld
Counterpoint: Routine Anti-Bacterial Prophylaxis Is Not Indicated in Neutropenic Patients With Hematological Malignancies
Michael Kleinberg
: 4127 – 4137 . 7 Engels EA Lau J Barza M . Efficacy of quinolone prophylaxis in neutropenic cancer patients: A meta-analysis . J Clin Oncol 1998 ; 16 : 1179 – 1187 . 8 Bow EJ Mandell LA Louie TJ . Quinolone-based antibacterial
Point: Fluoroquinolone-Based Antibacterial Chemoprophylaxis in Neutropenic Cancer Patients Works for Defined Outcomes in Defined Populations, but Must Be Used Wisely
Eric J. Bow
with cotrimoxazole for infection prophylaxis in acute leukemia: The trade-off for reduced gram-negative sepsis . Am J Med 1988 ; 84 : 847 – 854 . 29 Bow EJ Louie TJ . Emerging role of quinolones in the prevention of gram
Prevention and Treatment of Cancer-Related Infections
Lindsey Robert Baden, William Bensinger, Michael Angarone, Corey Casper, Erik R. Dubberke, Alison G. Freifeld, Ramiro Garzon, John N. Greene, John P. Greer, James I. Ito, Judith E. Karp, Daniel R. Kaul, Earl King, Emily Mackler, Kieren A. Marr, Jose G. Montoya, Ashley Morris-Engemann, Peter G. Pappas, Ken Rolston, Brahm Segal, Susan K. Seo, Sankar Swaminathan, Maoko Naganuma, and Dorothy A. Shead
Viridans group streptococcal bacteremia breakthroughs have been associated with quinolone prophylaxis, 26 , 78 , 79 which poses a concern given the potential for substantial morbidity and mortality associated with this pathogen in neutropenic patients
Infusion-Compatible Antibiotic Formulations for Rapid Administration to Improve Outcomes in Cancer Outpatients With Severe Sepsis and Septic Shock: The Sepsis STAT Pack
Jason D. Goldman, Amelia Gallaher, Rupali Jain, Zach Stednick, Manoj Menon, Michael J. Boeckh, Paul S. Pottinger, Stephen M. Schwartz, and Corey Casper
patients (67%) were de-escalated to an intravenous antipseudomonal cephalosporin and 71 of 156 (46%) were de-escalated to early-generation cephalosporin or quinolone. Of the 85 patients continuing Figure 2. Histogram of time from start of clinical
NCCN Guidelines Insights: Bladder Cancer, Version 2.2016
Peter E. Clark, Philippe E. Spiess, Neeraj Agarwal, Rick Bangs, Stephen A. Boorjian, Mark K. Buyyounouski, Jason A. Efstathiou, Thomas W. Flaig, Terence Friedlander, Richard E. Greenberg, Khurshid A. Guru, Noah Hahn, Harry W. Herr, Christopher Hoimes, Brant A. Inman, A. Karim Kader, Adam S. Kibel, Timothy M. Kuzel, Subodh M. Lele, Joshua J. Meeks, Jeff Michalski, Jeffrey S. Montgomery, Lance C. Pagliaro, Sumanta K. Pal, Anthony Patterson, Daniel Petrylak, Elizabeth R. Plimack, Kamal S. Pohar, Michael P. Porter, Wade J. Sexton, Arlene O. Siefker-Radtke, Guru Sonpavde, Jonathan Tward, Geoffrey Wile, Mary A. Dwyer, and Courtney Smith
have translated to patient refusal of BCG therapy. Local dysuria has been reported in 60% of patients in clinical trials. 8 Symptom management with single-dose, short-term quinolones and/or anticholinergics have been reported to reduce adverse events
Bladder Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology
Thomas W. Flaig, Philippe E. Spiess, Neeraj Agarwal, Rick Bangs, Stephen A. Boorjian, Mark K. Buyyounouski, Sam Chang, Tracy M. Downs, Jason A. Efstathiou, Terence Friedlander, Richard E. Greenberg, Khurshid A. Guru, Thomas Guzzo, Harry W. Herr, Jean Hoffman-Censits, Christopher Hoimes, Brant A. Inman, Masahito Jimbo, A. Karim Kader, Subodh M. Lele, Jeff Michalski, Jeffrey S. Montgomery, Lakshminarayanan Nandagopal, Lance C. Pagliaro, Sumanta K. Pal, Anthony Patterson, Elizabeth R. Plimack, Kamal S. Pohar, Mark A. Preston, Wade J. Sexton, Arlene O. Siefker-Radtke, Jonathan Tward, Jonathan L. Wright, Lisa A. Gurski, and Alyse Johnson-Chilla
. 56 However, the side effects are treatable in almost all cases, 57 and no increase in toxicity has been reported with cumulative doses. Symptom management with single-dose, short-term quinolones and/or anticholinergics have been reported to reduce
